As part of preliminary preparations for the autumn vaccination campaign, the Natsimbio holding (part of Rostec) has started developing new vaccines. The manufacturer promised to supply 70.6 million doses of flu drugs with an updated strain composition.
Updating the strain composition every year is an important stage of production, taking into account mutations of influenza viruses and allowing the creation of an effective vaccine. The enterprises in the holding's circuit operate on a full technological cycle — from independent production of the antigen to the finished dosage form. This approach ensures stability in supply, as well as eliminates dependence on foreign manufacturers
Of the entire batch of drugs, 56.5 million will be trivalent vaccines, and 14.1 million doses will be quadrivalent. Rostec also emphasized that the update of vaccines occurs annually after virologists identify new strains.
The main manufacturer of immunobiological drugs since 2015 has been Natsimbio. All products are manufactured in Russia and used within the framework of the national calendar of preventive vaccinations (NCPV).
It is worth recalling that at the beginning of this year, Russian scientists discovered a way to painless vaccine administration.
Read materials on the topic:
Almost 70 million doses of domestic flu vaccines sent to Russian regions